FDA Asked for Clarifying Points Before Your Next Submission — How to Scope Your Response

When FDA Asks Questions Before You Submit, the Clock Is Already Running

Receiving a request for clarifying information from FDA before a formal submission — whether through pre-submission feedback, an interactive review exchange, or a deficiency letter tied to a previous filing — can feel like a setback. It is not. It is an opportunity to shape the reviewer's expectations and narrow the gap between your evidence package and what FDA actually needs to make a decision.

But only if you respond correctly. An unfocused, over-scoped, or under-documented response can introduce new questions, delay your timeline, and erode reviewer confidence. This post walks through how to scope your response strategically, with the precision FDA expects.

Understand the Type of Request You Are Dealing With

Not all FDA clarifying requests carry the same weight or demand the same response strategy. Before drafting a single word, categorize the request:

• Pre-Submission (Q-Sub) written feedback: Governed by FDA's guidance 'Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program' (updated 2023), these responses are voluntary and set the tone for your eventual 510(k), De Novo, or PMA filing.
• Deficiency letters or Additional Information (AI) requests during review: These are formal and time-sensitive. Under 21 CFR Part 807 Subpart E, a failure to respond adequately to an AI request during a 510(k) review can result in a Not Substantially Equivalent (NSE) determination or an automatic withdrawal.
• Interactive review communications: FDA's interactive review policy, described in the 2014 guidance on 510(k) review practices, allows reviewers to request minor clarifications without issuing a formal AI request. These are low-friction but should still be treated with discipline.

Misclassifying the request type is one of the most common — and costly — mistakes early-stage device companies make.

Scope the Response Around the Question Asked — Not Around Everything You Know

The instinct to over-respond is understandable. When FDA raises a question about your biocompatibility testing rationale, the temptation is to submit every test report, every ISO 10993-1:2018 risk justification matrix, and three pages of narrative. Resist it.

FDA reviewers are working under review clock constraints. Under MDUFA V commitments, FDA targets 90-day total review time for standard 510(k)s. Burying a direct answer inside a document dump does not demonstrate thoroughness — it signals a lack of regulatory judgment.

Instead, structure your scoping process around three questions:

• What is the precise regulatory concern underlying the question? Map the FDA request back to the applicable regulation, recognized standard, or guidance document. A question about software validation is not the same as a question about software risk management, even if they feel adjacent.
• What is the minimum sufficient evidence to resolve that concern? Reference the specific standard — IEC 62304, ISO 14971, ASTM F2132, or whichever applies — and anchor your response to its requirements, not to a general description of your process.
• What should you explicitly not include? Proactively decide what is out of scope. If FDA asked about your predicate device comparison and not your clinical data, do not introduce clinical data unprompted unless it is directly necessary to answer the question. Volunteering information outside the scope of the question opens new review threads.

Structure Your Written Response for Reviewability

FDA reviewers are not reading your response in a vacuum — they are cross-referencing it against your original submission. Your response document needs a clear, navigable architecture:

• Open with a brief summary table that maps each FDA question to your response section and any supporting exhibit.
• Use the exact language of the FDA question as a header before each response. Do not paraphrase.
• Cite specific sections of your original submission when you are building on prior content, using the eCopy document structure your submission used.
• If you are amending data or correcting a prior statement, say so explicitly. FDA guidance on major and minor amendments (referenced in the 2019 'Refuse to Accept' guidance for 510(k)s) distinguishes between clarifications and substantive changes — know which category your revision falls into.

Red Flags That Expand Your Scope Unnecessarily

Several common drafting errors turn a focused response into a liability:

• Answering a question about one intended use with data that implies a broader or different indication — triggering a predicate mismatch concern.
• Submitting updated test reports with different revision numbers than those cited in your submission without a clear reconciliation note.
• Using language like 'we believe' or 'it is our understanding' without regulatory grounding — this invites follow-up questions.
• Referencing internal SOPs or design history file documents that FDA has not seen and did not request.

Coordinate Across Quality, Regulatory, and Clinical Before You Send

Responses to FDA clarifying requests frequently touch multiple disciplines. A question about software cybersecurity may require input from your engineering team, your quality management system documentation under 21 CFR Part 820 or ISO 13485:2016, and your regulatory affairs lead — all of whom may have different instincts about what to include. Establish a single owner for the response document and conduct a structured internal review against the original FDA question before submission. What looks complete from a technical perspective may still be non-responsive from a regulatory perspective.

Protect Your Timeline by Getting the Scope Right the First Time

Every round of back-and-forth with FDA after a formal submission consumes review clock time and, in some cases, resets it. A disciplined, well-scoped response is not just about professionalism — it is a direct investment in your approval timeline, your MDUFA commitments, and ultimately your path to market.

If you have received clarifying points from FDA before or during a submission and are unsure how to scope your response without overreaching or underdelivering, the regulatory team at ADB Consulting and CRO Inc. can help you get it right. Our practice directors bring deep, submission-specific experience across 510(k), De Novo, and PMA pathways. Book a free discovery call at adbccro.com and let us help you respond with precision.

Related reading: a structured Q-Sub meeting preparation process covers this in more depth.